Form D · Biotechnology

Centerline Biomedical, Inc.

Warrensville Heights, OH · CIK 0001998847

Offering snapshot reported Apr 25, 2025 · SEC filing

Reported sold
$10.8M
Offering amount: $15M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 11, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 25, 2025Initial$10,784,000No comparison8SEC filing
Nov 3, 2023Initial$13,650,000No comparison65SEC filing
Nov 3, 2023Initial$12,705,496No comparison106SEC filing
Nov 3, 2023Initial$34,675,000No comparison22SEC filing

Offering details

Securities
Equity, Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-544518

Source: Form D, filed Apr 25, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Indrani Egleston Executive
Vinod K. Goel Executive
Vikash Goel Executive
Jai N. Gupta Director
Gulam Khan Director, Executive
Arnaud Marie Director
Phil Rackliffe Director, Executive
Akhil Saklecha Director
Todd Schwarzinger Director
Karen Shanahan Director
Michael Whitman Director
Mitch Wolf Director
Jim Zalar Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4535 Renaissance Parkway
Warrensville Heights, OH, 44128